Company Overview and News

27
Why Is Cboe Global (CBOE) Down 7.5% Since its Last Earnings Report?

2018-06-04 zacks
It has been about a month since the last earnings report for Cboe Global Markets, Inc. (CBOE - Free Report) . Shares have lost about 7.5% in that time frame.
CBOE

27
CBOE / CBOE Holdings, Inc. null

2018-06-01 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8T(# @;V)J#3P\+TQI;F5A
CBOE

27
CBOE / CBOE Holdings, Inc. null

2018-06-01 sec.gov
[CBOE GLOBAL MARKETS, INC. LETTERHEAD] April 13, 2018
CBOE

27
CBOE / CBOE Holdings, Inc. null

2018-06-01 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8R(# @;V)J#3P\+TQI;F5A
CBOE

27
CBOE / CBOE Holdings, Inc. null

2018-06-01 sec.gov
[CBOE GLOBAL MARKETS, INC. LETTERHEAD] May 1, 2018
CBOE

27
CBOE / CBOE Holdings, Inc. null

2018-06-01 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED%[email protected]," P(#8Q,B W.3)=("]#;VYT96YT
CBOE

27
CBOE / CBOE Holdings, Inc. S-8

2018-05-18 sec.gov
As filed with the Securities and Exchange Commission on May 18, 2018 Registration No.&
CBOE

28
CBOE / CBOE Holdings, Inc. 8-K (Current Report)

2018-05-18 sec.gov
cboe_Current_Folio_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CBOE

104
Cboe Global (CBOE) Beats on Q1 Earnings, Revises Guidance

2018-05-07 zacks
Cboe Global Markets, Inc.’s (CBOE - Free Report) first-quarter 2018 adjusted earnings of $1.38 per share beat the Zacks Consensus Estimate of $1.27 by 8.7%. Moreover, the bottom line improved nearly 47% year over year.
CBOE 7018 CME UNP ODP MKTX RDUS

30
Cboe Global Markets' (CBOE) CEO Ed Tilly on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Cboe Global Markets, Inc. (NASDAQ:CBOE) Q1 2018 Earnings Conference Call May 4, 2018 8:30 AM ET
CBOE BATS

27
Volatility Strikes Back

2018-05-04 seekingalpha
By Sergei Antoshin, senior economist in the IMF’s Monetary and Capital Markets Department, Fabio Cortes, Economist in the IMF’s Monetary and Capital Markets Department, Will Kerry, deputy division chief in the IMF’s Monetary and Capital Markets Department and Thomas Piontek, financial sector expert in the Global Markets Analysis Division of the IMF’s Monetary and Capital Markets
CBOE APR APRLY

27
CBOE Holdings 2018 Q1 - Results - Earnings Call Slides

2018-05-04 seekingalpha
The following slide deck was published by CBOE Holdings in conjunction with their 2018 Q1 earnings call.
CBOE

27
CBOE / CBOE Holdings, Inc. 10-Q (Quarterly Report)

2018-05-04 sec.gov
cboe_Current_Folio_10Q Table of Contents
CBOE

29
CBOE / CBOE Holdings, Inc. 8-K (Current Report)

2018-05-04 sec.gov
cboe_Current_Folio_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CBOE

27
CBOE / CBOE Holdings, Inc. 8-K (Current Report)

2018-04-23 sec.gov
UNITED STATES<
CBOE

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 12503M108